Thryv Therapeutics Embarks on Pivotal Phase 2/3 Long QT Study with THRV-1268 Thryv Therapeutics has launched a pivotal Wave II clinical study examining THRV-1268, an oral SGK1 inhibitor for Long QT Syndrome Type 2. This study aims to advance treatment options for this serious condition.

Thryv Therapeutics Embarks on Pivotal Phase 2/3 Long QT Study with THRV-1268 #Canada #Montreal #Thryv_Therapeutics #Long_QT_Syndrome #THRV-1268

Thryv Therapeutics Reports Promising Phase 1 Findings for THRV-1268 in Obese Patients Thryv Therapeutics has announced positive Phase 1 results for THRV-1268, showcasing its potential in treating cardiovascular and metabolic conditions in obese participants.

Thryv Therapeutics Reports Promising Phase 1 Findings for THRV-1268 in Obese Patients #Canada #Montreal #Thryv_Therapeutics #SGK1_inhibitors #THRV-1268

Amy Rudolph, PhD, Appointed to Thryv Therapeutics' Board to Enhance Heart Failure Portfolio Thryv Therapeutics has appointed Dr. Amy Rudolph to its Board of Directors, bringing over 25 years of pharmaceutical expertise to support advancements in heart failure treatments.

Amy Rudolph, PhD, Appointed to Thryv Therapeutics' Board to Enhance Heart Failure Portfolio #Canada #Montreal #Thryv_Therapeutics #SGK1_inhibitors #Amy_Rudolph

Thryv Therapeutics to Unveil Breakthrough Research at 2025 AHA Sessions in New Orleans Thryv Therapeutics will present groundbreaking preclinical findings at the American Heart Association Scientific Sessions 2025, showcasing SGK1 inhibitors' potential.

Thryv Therapeutics to Unveil Breakthrough Research at 2025 AHA Sessions in New Orleans #USA #New_Orleans #Heart_Disease #Thryv_Therapeutics #SGK1_inhibitors

Thryv Therapeutics to Present Pipeline Innovations at Major Investor Conferences in 2025 Thryv Therapeutics announces participation in key healthcare investor conferences in late 2025 to share its advancements in SGK1 inhibitor therapies targeting cardiovascular diseases.

Thryv Therapeutics to Present Pipeline Innovations at Major Investor Conferences in 2025 #Canada #Montreal #Thryv_Therapeutics #SGK1_inhibitors #Cardiovascular_Diseases

Thryv Therapeutics Secures FDA Approval for THRV-1268 to Combat Long QT Syndrome Thryv Therapeutics has received FDA IND clearance for THRV-1268, a significant step towards addressing Long QT Syndrome with upcoming clinical trials.

Thryv Therapeutics Secures FDA Approval for THRV-1268 to Combat Long QT Syndrome #Canada #Montreal #Thryv_Therapeutics #Long_QT_Syndrome #THRV-1268

Thryv Therapeutics Achieves FDA Clearance for THRV-1268's Heart Failure Programs and Presents New Findings Thryv Therapeutics has received FDA clearance for THRV-1268 and shared promising preclinical results at ESC Congress 2025, marking a significant advance in heart failure treatment.

Thryv Therapeutics Achieves FDA Clearance for THRV-1268's Heart Failure Programs and Presents New Findings #Canada #Montreal #Thryv_Therapeutics #THRV-1268 #Jardiance

Thryv Therapeutics to Showcase Promising Cardiac Research at 2025 ESC Congress in Madrid Thryv Therapeutics is set to present groundbreaking preclinical data at the upcoming European Society of Cardiology Congress 2025 in Madrid, Spain.

Thryv Therapeutics to Showcase Promising Cardiac Research at 2025 ESC Congress in Madrid #Canada #Montreal #Thryv_Therapeutics #SGK1_inhibitors #Long_QT_Syndrome

Thryv Therapeutics to Share Innovative Clinical Findings at Healthcare Conferences in New York Thryv Therapeutics, a biotechnology firm, will present recent findings on SGK1 inhibitors at major healthcare investor events in New York City, showcasing exciting developments.

Thryv Therapeutics to Share Innovative Clinical Findings at Healthcare Conferences in New York #Canada #Montreal #Thryv_Therapeutics #SGK1_inhibitors #Long_QT_Syndrome

Thryv Therapeutics Set to Showcase Innovations at 2025 Piper Sandler Virtual Cardio Day Thryv Therapeutics is excited to participate in the 2025 Piper Sandler Virtual Cardio Day, highlighting their advancements in cardiovascular treatments.

Thryv Therapeutics Set to Showcase Innovations at 2025 Piper Sandler Virtual Cardio Day #Canada #Montreal #Thryv_Therapeutics #SGK1_inhibitors #Long_QT_Syndrome

Thryv Therapeutics Set to Join the 2025 Leerink Partners Global Healthcare Conference in Miami, FL Thryv Therapeutics is preparing to attend the prestigious Leerink Partners Global Healthcare Conference in Miami, Florida from March 10-12, 2025. Join us for insights and networking.

Thryv Therapeutics Set to Join the 2025 Leerink Partners Global Healthcare Conference in Miami, FL #United_States #Miami #Healthcare_Conference #Thryv_Therapeutics #Cardiovascular_Therapies

Thryv Therapeutics Set to Showcase Innovations at J.P. Morgan Healthcare Conference 2025 Thryv Therapeutics Inc. will participate in the prestigious 2025 J.P. Morgan Healthcare Conference, showcasing its cardiovascular disease therapies.

Thryv Therapeutics Set to Showcase Innovations at J.P. Morgan Healthcare Conference 2025 #United_States #San_Francisco #Healthcare_Conference #J.P._Morgan #Thryv_Therapeutics